A. Bergman

发表

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes

G. Herman, A. Bergman, B. Yi, 2006, Current medical research and opinion.

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

B. Feng, T. Goosen, Y. Lai, 2012, Pharmaceutical Research.

Effect of Hepatic Organic Anion‐Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver‐Targeted Glucokinase Activator: A Model‐Based Evaluation

J. Pfefferkorn, D. Kazierad, M. Varma, 2019, Clinical pharmacology and therapeutics.

Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling

F Kesisoglou, W. S. Denney, P. Lu, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction

M. Birnbaum, G. Sonnenberg, J. Pfefferkorn, 2021, Molecular metabolism.

Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System

T. Maurer, D. Scott, S. Steyn, 2016, Pharmaceutical Research.

Model-Based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

A. Bergman, J. Wagner, R. Krishna, 2011, The AAPS Journal.

Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans

D. Dean, Sanjeev Kumar, A. Bergman, 2010, Drug Metabolism and Disposition.

Assessment of the CYP3A‐Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers

A. Bergman, J. Wagner, R. Krishna, 2009, Journal of clinical pharmacology.

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

L. V. Van Bortel, A. Bergman, J. Wagner, 2009, British journal of clinical pharmacology.

Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans

A. Kalgutkar, A. Bergman, T. E. Ballard, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.

G. Herman, A. Bergman, J. Wagner, 2009, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

Response to the Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”

B. Feng, T. Goosen, Y. Lai, 2013, Pharmaceutical Research.

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Donal N. Gorman, A. Bergman, Donal N Gorman, 2021, Nature Medicine.

Efficacy and safety of the glucagon receptor antagonist PF‐06291874: A 12‐week, randomized, dose‐response study in patients with type 2 diabetes mellitus on background metformin therapy

D. Kazierad, A. Bergman, V. Somayaji, 2018, Diabetes, obesity & metabolism.

Multiple‐Dose Administration of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Does Not Alter the Single‐Dose Pharmacokinetics of Rosiglitazone in Healthy Subjects

G. Herman, A. Bergman, J. Wagner, 2007, Journal of clinical pharmacology.

Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects.

G. Herman, A. Bergman, J. Wagner, 2008, British journal of clinical pharmacology.

A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.

D. Kazierad, A. Bergman, V. Somayaji, 2017, Diabetes research and clinical practice.

Effects of multiple ascending doses of the glucagon receptor antagonist PF‐06291874 in patients with type 2 diabetes mellitus

T. Rolph, D. Erion, D. Kazierad, 2016, Diabetes, obesity & metabolism.

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

M. Inglot, T. Tuthill, J. Pfefferkorn, 2021, Nature Medicine.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

S. Tarabar, A. Bergman, W. Esler, 2020, Clinical pharmacology in drug development.

A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects

G. Herman, A. Bergman, J. Wagner, 2009, Journal of clinical pharmacology.

Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [ 14 C ] Sitagliptin in Humans

W. Zeng, S. Xu, G. Herman, 2007 .

Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans

W. Zeng, S. Xu, G. Herman, 2007, Drug Metabolism and Disposition.

Mini‐Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study

R Scott Obach, Danny Chen, Douglas K Spracklin, 2020, CPT: pharmacometrics & systems pharmacology.

PS-110-Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with non-alcoholic fatty liver disease

D. Kazierad, A. Bergman, V. Somayaji, 2019, Journal of Hepatology.

Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers

S. Waldman, T. Bradstreet, P. Rothenberg, 2006, Journal of clinical pharmacology.

PIII‐60

W. Zeng, W. Smith, G. Herman, 2006 .

Effect of a Ketohexokinase Inhibitor (PF‐06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug

A. D. Rodrigues, M. Varma, A. Bergman, 2022, Clinical pharmacology and therapeutics.

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers

W. Zeng, G. Herman, A. Bergman, 2007, Biopharmaceutics & drug disposition.

Safety, tolerability, pharmacokinetics and pharmacodynamics of a liver-targeting ACC inhibitor (PF-05221304) following single and multiple oral doses

S. Tarabar, A. Bergman, W. Esler, 2018 .

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir

G. Nucci, P. Chan, A. Bergman, 2022, medRxiv.

Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects.

J. Paolini, A. Bergman, B. Yi, 2006, International journal of clinical pharmacology and therapeutics.

Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug Development

G. S. Walker, A. Kalgutkar, A. Bergman, 2022, Clinical pharmacology and therapeutics.

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses

W. Zeng, G. Herman, A. Bergman, 2005, Clinical pharmacology and therapeutics.

Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein

Shiyao Xu, Arthur J Bergman, X. Chu, 2007, Journal of Pharmacology and Experimental Therapeutics.

Ezetimibe

J. Paolini, A. Bergman, K. Alton, 2005, Clinical pharmacokinetics.

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

J. Holst, W. Zeng, C. Deacon, 2006, The Journal of clinical endocrinology and metabolism.

De novo lipogenesis is essential for platelet production in humans

G. Sonnenberg, J. Pfefferkorn, M. Hellerstein, 2020, Nature Metabolism.

Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin

P. Rothenberg, A. Bergman, D. Panebianco, 2005, European Journal of Clinical Pharmacology.

Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects

W. Zeng, G. Herman, A. Bergman, 2006, Journal of clinical pharmacology.

Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Does Not Affect the Pharmacokinetics of Ethinyl Estradiol or Norethindrone in Healthy Female Subjects

A. Bergman, J. Wagner, K. Lasseter, 2011, Journal of clinical pharmacology.

Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.

W. Zeng, G. Herman, A. Bergman, 2011, British journal of clinical pharmacology.

Effect of Sitagliptin on the Pharmacokinetics of Simvastatin

G. Herman, A. Bergman, B. Keymeulen, 2009, Journal of clinical pharmacology.

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

John A Wagner, Rajesh Krishna, Arthur J Bergman, 2007, The Lancet.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

W. Zeng, G. Herman, A. Bergman, 2006, Clinical therapeutics.

Assessment of pharmacokinetic interactions between ezetimibe and cyclosporine

J. Paolini, A. Bergman, T. Kosoglou, 2005 .

Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans

J. Paolini, A. Hartford, A. Bergman, 2004, Journal of clinical pharmacology.

Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial.

M. Birnbaum, D. Kazierad, A. Bergman, 2021, Med.

Dose‐proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers

W. Zeng, G. Herman, A. Bergman, 2007, Biopharmaceutics & drug disposition.

Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects

W. Zeng, G. Herman, A. Bergman, 2007, Journal of clinical pharmacology.

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

B. Feng, T. Goosen, Y. Lai, 2012, Pharmaceutical Research.

Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs

A. D. Rodrigues, S. Yamazaki, M. Varma, 2022, Clinical pharmacology and therapeutics.

Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects

Anup Majumdar, A. Bergman, K. Lasseter, 2007, Journal of clinical pharmacology.

Effect of Different Durations and Formulations of Diltiazem on the Single‐Dose Pharmacokinetics of Midazolam: How Long Do We Go?

John A Wagner, Arthur J Bergman, J. Chodakewitz, 2011, Journal of clinical pharmacology.

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects

J. Paolini, W. Kraft, H. Greenberg, 2006, Journal of clinical pharmacology.

Interaction of Single‐Dose Ezetimibe and Steady‐State Cyclosporine in Renal Transplant Patients

J. Paolini, A. Bergman, R. Robson, 2006, Journal of clinical pharmacology.

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus

Donal N. Gorman, A. Bergman, K. Furihata, 2022, Diabetes, obesity & metabolism.

Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment

A. Kalgutkar, J. Pfefferkorn, L. Di, 2015, Drug Metabolism and Disposition.

Effect of Impaired Renal Function and Haemodialysis on the Pharmacokinetics of Aprepitant

T. Bradstreet, S. Swan, A. Bergman, 2005, Clinical pharmacokinetics.

Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies

A. Kalgutkar, D. Kazierad, A. Bergman, 2019, Xenobiotica; the fate of foreign compounds in biological systems.

Multiple‐Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

D. Bloomfield, L. Bortel, O. Laterza, 2008, Clinical pharmacology and therapeutics.

Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans

D. Dean, Sanjeev Kumar, A. Bergman, 2010, Drug Metabolism and Disposition.

Assessment of the CYP3A‐Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers

A. Bergman, J. Wagner, R. Krishna, 2009, Journal of clinical pharmacology.